Boehringer Ingelheim increases access to the medication for the treatment of HIV/AIDS

Boehringer IngelheimBoehringer Ingelheim is announcing an expansion of its Intellectual Property (IP) enforcement policy. The IP enforcement policy had already been amended in 2007 by an easy-to-use, non-assert declaration for Viramune® (nevirapine). At present, twelve WHO pre-qualified manufacturers qualify for the non-assert declaration for Viramune® and Boehringer Ingelheim grants tiered pricing to 78 countries.

Under the revised IP enforcement policy, Boehringer Ingelheim will not enforce its nevirapine patent rights, provided generic versions of Viramune® are of acceptable quality and for use in eligible countries. Today's expanded IP enforcement policy will further increase access to HIV/Aids medication in emerging economies.

The decision to waive enforcement of its patent rights for nevirapine use in a total of 135 low- and middle-income countries is the result of a close cooperation between Boehringer Ingelheim and the Medicines Patent Pool (MPP). The United Nations-backed public health organisation MPP works to improve access to HIV, Hepatitis C and tuberculosis medicines in low- and middle-income countries.

"The core task of Boehringer Ingelheim is the research and development of innovative medication. We feel responsible for making innovative medicines like nevirapine accessible and affordable for patients in developing countries," explains Yew Looi Liew, Senior Vice President Emerging Markets at Boehringer Ingelheim. "Through making these medicines available we address an unmet medical need and can save lives - especially in low-income societies."

The research-driven company Boehringer Ingelheim has a significant history in the commitment of improving access to its anti-retroviral medication. The Viramune® Donation Programme was initiated in 2000 in order to facilitating access of anti-retroviral drugs for pregnant women with HIV/Aids. From its inception, the initiative reached more than two million mother-child-pairs in 164 programmes in 60 countries worldwide.

The Medicines Patent Pool (MPP) seeks to increase access to medicines by negotiating with pharmaceutical companies for voluntary licenses on their medicines patents. The work of the MPP has been endorsed by the World Health Organization, UNAIDS, The Global Fund to Fight Aids, Tuberculosis and Malaria, and the Group of Eight (G8) Industrialised Nations (France, Germany, Italy, United Kingdom, Japan, United States, Canada and Russia). The MPP was founded and continues to be funded by the innovative financing mechanism UNITAID.

About Boehringer Ingelheim
Boehringer Ingelheim is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects through, for example, the initiative "Making More Health" while also caring for employees. Respect, equal opportunity and reconciling career and family form the foundation of mutual cooperation. The company also focuses on environmental protection and sustainability in everything it does.

In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent ofnet sales.

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Sanofi and Regeneron provide update on Kevzara® (s…

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical v...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Another mRNA-based vaccine candidate protects anim…

An experimental messenger RNA (mRNA)-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits protective immune responses in mice and no...

Pfizer and BioNTech announce an agreement with U.S…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of...

Pfizer and BioNTech announce agreement with the Un…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candid...